Novartis CEO Warns US-China Biotech Curbs
Novartis CEO Vas Narasimhan warned on Bloomberg TV that US-China biotech curbs could limit technology exchange, hindering R&D and market access. The Treasury Department proposed including biotech in investment limits for foreign adversaries, affecting multinational drugmakers like Novartis. Restrictions may slow drug development and access to key markets.
How this was made

The 30-second read
Why it matters
The expansion could force Novartis and other Western drugmakers to restructure cross‑border projects, influencing pipeline timelines and market access.
Market read
Regulatory tightening on biotech could affect valuation of global pharma stocks, especially those with significant China exposure.
What to watch
Potential for alternative supply chains or increased domestic R&D investment in the US and Europe could mitigate the impact.
Background
The US Treasury is expanding the COINS Act to include biotechnology among sensitive technologies, following similar moves for AI, semiconductors, and quantum computing.
Ticker impact
Novartis CEO Vas Narasimhan warned that upcoming US biotech investment limits could restrict the company's R&D and market access in China and the US.
likely downside pressure as investors price in possible revenue and pipeline constraints
The CEO’s remarks signal a possible new regulatory environment that could affect Novartis' ability to develop and sell drugs internationally, a material risk factor.
Market effects
US and European biotech firms may face heightened scrutiny and investment limits, potentially tightening capital flows to China.
European pharma stocks could see modest pressure; Chinese biotech may experience reduced foreign partnership opportunities.
The policy could reshape global biotech collaboration dynamics, affecting multinational drugmakers beyond Novartis.
Counterpoint
If the curbs are limited in scope, the market may overreact; Novartis could benefit from a first‑mover advantage in compliant R&D.
Key entities
- companyNovartis AG
Swiss multinational pharmaceutical company, US‑listed via ADR NVS.
- executiveVas Narasimhan
CEO of Novartis, providing the primary quote.
- governmentUS Treasury Department
Agency proposing the biotech investment limits under the COINS Act.




